Clinical presentations of hemophagocytic lymphohistiocytosis (HLH) and septic shock share many similarities, including multiple organ dysfunction and overall clinical and biological symptoms. However, these life-threatening conditions require specific and opposing treatments. Currently, no single biomarker is available to differentiate septic shock from HLH at patient admission \[[@CR1], [@CR2]\]. HLH is classified as a primary (genetically inherited) or a secondary, i.e., induced by various inflammatory conditions (viral infections, autoimmune processes, lymphoid malignancies, or drug allergies), immune disorder. We report here the case of a young woman with febrile shock which proved to be a HLH caused by drug-induced hypersensitivity syndrome (DIHS). As septic shock was initially suspected, the patient benefited from broad immunological screening during the first week of evolution \[[@CR3]\]. Strikingly, this revealed massively increased expression of monocyte human leukocyte antigen-DR (mHLA-DR) at 137,021 ABC (antibody bound per cell), even though expected values in septic shock are usually drastically decreased \[[@CR3]\]. In addition, a positive response to increasing doses of corticosteroids was observed over time (Fig. [1](#Fig1){ref-type="fig"}). More precisely, while the patient's mHLA-DR expression was measured at 137,021 ABC at admission, it decreased to 38,961 ABC after the introduction of corticosteroids (day 3). Following the reactivation of inflammatory processes (day 5), mHLA-DR rose again (66,829 ABC). Finally, mHLA-DR returned to a normal range after increasing corticosteroid doses (20,499 ABC, day 8). All clinical features are provided in Additional file [1](#MOESM1){ref-type="media"}.Fig. 1Time course of mHLA-DR in a HLH patient. *Blue squares* depict mHLA-DR values in the HLH patient. *Red circles* represent pediatric septic shock values \[[@CR3]\]. *Gray range* represents interquartile range values obtained previously in healthy children \[[@CR3]\]. \*Corticosteroids introduced, receiving 2 mg/kg/day; \*\*corticosteroid adjustment to 4 mg/kg/day

In the present patient, the extremely increased inaugural mHLA-DR value (i.e., 137,021 ABC) helped to unequivocally exclude a diagnosis of septic shock. Indeed, in our experience (more than 600 septic shock patients monitored over several years), the vast majority of mHLA-DR values measured within the first 3 days after septic shock are reported to be \< 30,000 ABC and mostly found below 10,000 ABC (normal values ranged from 15,000 to 40,000 ABC). This agrees with pathophysiology since HLH is secondary to overproduction of interferon-γ (IFN-γ), a cytokine known to be a strong inducer of mHLA-DR expression, whereas sepsis induces downregulation of mHLA-DR expression.

In conclusion, mHLA-DR may discriminate septic shock from HLH at admission despite both situations with multiple organ dysfunction sharing very common clinical and biological features (e.g., sCD25, elevated ferritin levels) \[[@CR4], [@CR5]\]. This result obviously needs further assessment in various types of HLH. Upon confirmation, as these two deadly conditions (i.e., septic shock and HLH) would require opposing treatments, mHLA-DR may be of crucial help for clinicians regarding patients' care and management.
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ABC

:   Antibody bound per cell

DIHS

:   Drug-induced hypersensitivity syndrome

HLH

:   Hemophagocytic lymphohistiocytosis

IFN-γ

:   Interferon-γ

mHLA-DR

:   Monocyte human leukocyte antigen-DR
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